Source: http://www.google.com/patents/US8030350?dq=inventor:%22Arthur+R.+Hair%22&ei=VAy0Tsa4NYTl0QGQiqWiBA
Timestamp: 2017-11-20 06:08:17
Document Index: 491139050

Matched Legal Cases: ['application No. 2003265617', 'Application No. 2', 'Application No. 2477245', 'Application No. 2537210', 'Application No. 03826969', 'Application No. 03804566', 'Application No. 03804566', 'application No. 584433', 'application No. 10']

Patent US8030350 - Trans carotenoids, their synthesis, formulation and uses - Google Patents
The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans....http://www.google.com/patents/US8030350?utm_source=gb-gplus-sharePatent US8030350 - Trans carotenoids, their synthesis, formulation and uses
Publication number US8030350 B2
Application number US 11/361,054
Also published as CA2598882A1, CN101180257A, CN104840455A, EP1853544A2, EP1853544A4, EP2540696A1, US20060194973, US20120095099, US20160199490, WO2006104610A2, WO2006104610A3
Publication number 11361054, 361054, US 8030350 B2, US 8030350B2, US-B2-8030350, US8030350 B2, US8030350B2
Inventors John L. Gainer, Marc Lanz
Original Assignee Diffusion Pharmaceuticals Llc
Patent Citations (62), Non-Patent Citations (180), Referenced by (4), Classifications (15), Legal Events (2)
US 8030350 B2
61. A method as in claim 16 or 23 wherein the pendant groups X, which can be the same or different, are selected from the group consisting of methyl groups (CH3) and ethyl groups (C2H5).
Z (which can be the same or different at the two ends)=polar group which is associated with the H or cation. Optionally including the terminal carbon on the carotenoid (or carotenoid related compound), this group can be a carboxyl (COO−) group or a CO group (e.g. ester, aldehyde or ketone group), or a hydroxyl group. This group can also be a sulfate group (OSO3 −) or a monophosphate group (OPO3 −), (OP(OH)O2 −), a diphosphate group, triphosphate or combinations thereof. This group can also be an ester group of COOR where the R is CnH2n+1.
E-027758-001– 97.88 White Powder Complies
3. Butylene oxide (3) and toluene (4) were charged to the reactor at JT=20° C. The 100 reactor was evacuated and purged with nitrogen twice. The reaction mixture was warmed to JT=100° C. A homogenous solution was obtained. The used materials was a salt mixture containing 48% bromide and 52% chloride to the CoA of The supplier. Thus, the real mass was different from the theoretical one as depicted on the formula scheme.
Chemicals: Acetonitrile, HPLC grade (J.T. Baker or equivalent)
Trifluoroacetic acid (Merck or equivalent)
THF, HPLC grade, without stabilizer (Scharlau or equivalent)
MeOH, HPLC grade (Scharlau or equivalent)
Example 3 Synthesis of Trans Potassium Crocetinate (di-potassium 2,6,11,15-tetramethylhexadeca-2E,4E,6E,8E,10E,12E,14E,-heptane-1,16-diotate)
Example 4 Synthesis of Trans Lithium Crocetinate (di-lithium 2,6,11,15-tetramethylhexadeca -2E,4E,6E,8E,10E,12E,14E,-heptane-1,16-diotate)
Example 5 Synthesis of the C-14 Derivative of TSC (disodium 4,9-dimethyldodeca -2E,4E,6E,8E,10E-pentane-1,12 diotate)
Example 6 Synthesis of the C-15 Derivative of TSC (disodium 2,4,9-Trimethyldodeca -2E,4E,6E,8E,10Epentaene-1,12-diotate)
Example 7 Synthesis of the C-16 Derivative of TSC (disodium 2,4,9,11-Tetramethyldodedeca -2E,4E,6E,8E,10E-pentaene-1,12-diotate)
Example 8 Synthesis of the C-17 Derivative of TSC (disodium 2,6,11-Trimethyltetradeca -2E,4E,6E,8E,10E,12Ehexaene-1,14-diotate)
Example 9 Synthesis of the C-18 Derivative of TSC (Disodium 2,4,9,13-Tetramethyltetradeca -2E,4E,6E,8E,10E,12Ehexaene-1,14-diotate)
Example 10 Synthesis of the C-24 Derivative of TSC (Disodium 4,8,13,17-Tetramethyleicosa -2E,4E,6E,8E,10E,12E,14E,16E,18Enonaene-1,10-diotate)
Example 11 Synthesis of the C-26 Derivative of TSC (Disodium 2,4,8,13,17,19-Hexamethyleicosa -2E,4E,6E,8E,10E,12E,14E,16E,18Enonaene-1,10-diotate)
US2175843 Jun 19, 1937 Oct 10, 1939 Winthrop Chem Co Inc Polyene carboxylic acids and esters and manufacture thereof
US2948748 * Nov 24, 1958 Aug 9, 1960 Esters thereof
US3489806 Jan 19, 1967 Jan 13, 1970 Hoffmann La Roche Isoprenoid compounds and a process for producing the same
US3687990 Jul 1, 1969 Aug 29, 1972 Hoffmann La Roche Isoprenoid compounds and a process for producing the same
US3788468 May 1, 1973 Jan 29, 1974 Univ Virginia Process for increasing oxygen diffusivity
US3853993 Jun 28, 1973 Dec 10, 1974 Univ Virginia Process for increasing oxygen diffusivity and method for treating atherosclerosis
US3965261 Apr 29, 1975 Jun 22, 1976 University Of Virginia Method for treating papillomas
US3975519 Jun 9, 1975 Aug 17, 1976 University Of Virginia Method for increasing the oxygen partial pressure in the bloodstream of mammals
US4009270 Nov 21, 1975 Feb 22, 1977 The University Of Virginia Method for treating spinal cord injury
US4038144 * Apr 19, 1976 Jul 26, 1977 The University Of Virginia Method of increasing fermentation yields
US4046880 * Apr 20, 1976 Sep 6, 1977 The University Of Virginia Method of treating hypertension
US4070460 Nov 10, 1975 Jan 24, 1978 University Of Virginia Patents Foundation Method for treating cerebral edema
US4105855 * Jan 26, 1976 Aug 8, 1978 Basf Aktiengesellschaft Manufacture of symmetrical carotenoids
US4176179 Apr 17, 1978 Nov 27, 1979 The University Of Virginia Alumni Patents Foundation Method for treating arthritis
US4216211 Oct 31, 1977 Aug 5, 1980 The Procter & Gamble Company Therapeutic composition
US5053240 Oct 24, 1989 Oct 1, 1991 Kalamazoo Holdings, Inc. Norbixin adducts with water-soluble or water-dispersible proteins or branched-chain or cyclic polysaccharides
US5107030 Mar 4, 1991 Apr 21, 1992 Loyola University Of Chicago Method of making 2,7-dimethyl-2,4,6-octatrienedial and derivatives thereof
US5424407 * Nov 22, 1993 Jun 13, 1995 Ensuiko Sugar Refining Co., Ltd. Crocetin-containing coloring
US6060511 Oct 3, 1996 May 9, 2000 Gainer; John L. Trans-sodium crocetinate, methods of making and methods of use thereof
US6150561 * Sep 4, 1998 Nov 21, 2000 Roche Vitamins Inc. Method of making carotenoids
US7446101 Dec 12, 2003 Nov 4, 2008 Bioactives, Llc Bioavailable carotenoid-cyclodextrin formulations for soft-gels and other encapsulation systems
US20030180282 Mar 25, 2002 Sep 25, 2003 Victor Serebruany Method of treatment of thrombotic events
US20040109920 Dec 4, 2002 Jun 10, 2004 Bioactives Llc Coated carotenoid cyclodextrin complexes
US20060194973 Feb 24, 2006 Aug 31, 2006 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
US20070088248 Sep 5, 2006 Apr 19, 2007 Iomai Corporation Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof
US20080255246 Apr 11, 2008 Oct 16, 2008 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
CH522572A Title not available
EP0908449A1 Sep 28, 1998 Apr 14, 1999 F. Hoffmann-La Roche Ag Preparation of carotenoids
JP45014114A Title not available
JP2002524535A Title not available
JP2005518453A Title not available
JPH0326607A Title not available
JPH0356412A Title not available
JPH0532531A Title not available
JPH0723736A Title not available
JPH04264020A Title not available
JPH05178765A Title not available
JPH06248193A Title not available
JPH07223960A Title not available
JPH07291854A Title not available
JPH10502388A Title not available
JPH11180901A Title not available
JPH11209642A Title not available
JPS6359831A Title not available
JPS61254161A Title not available
KR19990036861A Title not available
WO1992015544A1 Feb 25, 1992 Sep 17, 1992 Loyola University Of Chicago Method of making 2,7-dimethyl-2,4,6-octatrienedial and derivatives thereof
WO1995000130A1 Jun 28, 1994 Jan 5, 1995 The Howard Foundation Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism
WO1998014183A1 Oct 2, 1997 Apr 9, 1998 The University Of Virginia Patent Foundation Trans-sodium crocetinate, methods of making and methods of use thereof
WO2003072734A2 Feb 25, 2003 Sep 4, 2003 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
WO2004048323A1 Nov 17, 2003 Jun 10, 2004 Basf Aktiengesellschaft Method for producing carotenoids
WO2005028411A1 Aug 25, 2003 Mar 31, 2005 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
WO2006039685A2 Oct 3, 2005 Apr 13, 2006 Hawaii Biotech, Inc. Methods for synthesis of chiral intermediates of carotenoids, carotenoid analogs, and carotenoid derivatives
WO2006104610A2 Feb 24, 2006 Oct 5, 2006 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
WO2007072529A2 Dec 4, 2006 Jun 28, 2007 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the synthesis of intermediates for the preparation of astaxanthin
1 Ahmad, A.S., et al, Pharmacology Biochemistry and Behavior, 81 (2005) pp. 805-813, "Neuroprotection by cretin in a hemi-parkinsonian rat model."
2 Australian Office Action dated Mar. 26, 2010 in applicant's Australian application No. 2003265617.
3 Bennett, MH, et al, Hyperbaric oxygen therapy for late radiation tissue injury (Review), Copyright 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Issue 2.
4 Britton, G. et al, Carotenoids, vol. 1A, Birkhauser-Verlag, Basel, 1995, p. 7, 35.
5 Buchta and Andree, Naturwiss, The Total Synthesis of trans-2,2-Bisdimethyl-crocetin-dimetyl ester and trans-Crocetin-dimethyl ester, (1959).
6 Buchta, E. and Andree, F., Chem. Ber. 93, 1349 (1960).
7 Bui, Q-C, et al, Int. J. Radiation Oncology Biol. Phys., vol. 60, No. 3, pp. 871-878, (2004), "The Efficacy of Hyperbaric Oxygen Therapy in the Treatment of Radiation-Induced Late Side Effects."
8 Calvo, W., et al, The British Journal of Radiology, 61, pp. 1043-1052, (1988), "Time-and dose-related changes in the white matter of the rat brain after single doses of X rays."
9 Calvo, W., et al, The British Journal of Radiology, 61, pp. 1043-1052, (1988), "Time—and dose-related changes in the white matter of the rat brain after single doses of X rays."
10 Canadian Office Action dated Oct. 20, 2009 from Canadian Application No. 2,477,245.
11 Canadian Office Action issued Jul. 7, 2010 in corresponding Canadian Application No. 2477245.
12 Canadian Office Action issued Oct. 26, 2010 in corresponding Canadian Application No. 2537210.
13 Carotenoids vol. 1A: Isolation and Analysis, Edited by G. Britton, S. Liaaen-Jensen and H. Pfander, Birkhauser Verlag, Basel, 1995, pp. 103-107; p. 283.
14 * Chem. Abstr. of JP 05032531.
15 Chinese Office Action and its English Translation dated Feb. 12, 2010 in the Assignee's Chinese application relating to PCT/US 06/06422.
16 Chinese Office Action dated Mar. 29, 2010 from Chinese Patent Application No. 03826969.4 based on PCT/US03/26424.
17 Chinese Office Action dated Nov. 7, 2008 in a corresponding application owned by the applicants (Chinese App No. 03826969.4).
18 Chinese Patent Office-Third Office Action in Chinese Patent Application No. 03804566.4 dated Jan. 23, 2009.
19 Chinese Patent Office—Third Office Action in Chinese Patent Application No. 03804566.4 dated Jan. 23, 2009.
20 Cianci, P, (see Cianci, P., Hyperbaric therapy for radiation injury, in "Radiation Injury, Advances in Management and Prevention" edited by J.L. Meyer, et al, pp. 98-109, (1999)).
21 Coppola, G.M., Syn. Communications 1021 (Dec. 1984).
22 Craw, M., and Lambert, C., Photochemistry and Photobiology, vol. 38 (2), pp. 241-243 (1983).
23 Craw, M., et al, Photochemitry and Photobiology, vol. 38 (2), 241-243 (1983).
24 CRC Handbook of Chemistry and Physics, edited by D.R. Lide, Ph.D., CRC Press, Boca Raton, FL, 6-181, 1998.
25 Cutright, D.E., et al, Radiation Research, 48, pp. 402-408 (1971) "Long-Term Effects of Radiation on the Vascularity of Rat Bone-Quantitative Measurements with a New Technique."
26 Cutright, D.E., et al, Radiation Research, 48, pp. 402-408 (1971) "Long-Term Effects of Radiation on the Vascularity of Rat Bone—Quantitative Measurements with a New Technique."
27 Database Caplus Chemical Abstracts Service, Columbus, Ohio (XP002317165), 1989.
28 Database Caplus Chemical Abstracts Service, Columbus, Ohio (XP002317165).
29 Database Caplus Chemical Abstracts Service, Columbus, Ohio (XP002317166), 1993.
30 Database Caplus Chemical Abstracts Service, Columbus, Ohio (XP002317166).
31 Database Caplus, Chemical Abstracts Service, Columbus, Ohio, US; (XP002317165) [JP 63 059831].
32 Database Caplus, Chemical Abstracts Service, Columbus, Ohio, US; (XP002317166) [JP 05 032531].
33 Database Caplus, Chemical Abstracts Service, Columbus, Ohio, US; XP002317165 (1988) [JP 63 059831].
34 Database Caplus, Chemical Abstracts Service, Columbus, Ohio, US; XP002317165 [Japan 63 059831], 1988.
35 Database Caplus, Chemical Abstracts Service, Columbus, Ohio, US; XP002317165 [JP 63 059831].
36 Database Caplus, Chemical Abstracts Service, Columbus, Ohio, US; XP002317166 (1993) [JP 05 032531].
37 Database Caplus, Chemical Abstracts Service, Columbus, Ohio, US; XP002317166 [Japan 05 032531], 1998.
38 * Database HCAPLUS on STN, DN 141:388250, Magesh, V. "Studies on the anti-tumor effect of crocetin against 3enzo(a)pyrene induced lung cancer in Swiss albino mice." Biomedicine, (Chennai, India) (2003), 23 (3 & 4), 96-99,Abstract.
39 Database HCAPLUS on STN, DN 141:388250, Magesh, V. "Studies on the anti-tumor effect of crocetin against benzo(a)pyrene induced lung cancer in Swiss albino mice." Biomedicine, (Chennai, India) (2003), 23 (3 & 4), 96-99, Abstract.
40 Denninghoff et al, Diabetes Technology & Therapeutics, vol. 2, No. 1, pp. 111-113 (2000).
41 EPO Office Action dated Nov. 9, 2009 in applicant's European application corresponding to PCT/US03/26424.
42 Examination Report dated Apr. 12, 2010 issued by the India Patent Office in one of Applicants' corresponding foreign applications.
43 Examination Report dated Apr. 7, 2010 issued by the New Zealand Patent Office in Applicants' corresponding foreign application No. 584433.
44 Examination Report dated Jan. 8, 2008 from corresponding New Zealand Patent Office.
45 Examination Report dated Jul. 2, 2009 issued by the New Zealand Patent Office in one of Applicants' corresponding foreign applications.
46 Examination Report dated Oct. 25, 2010 issued by the Australian Patent Office in one of Applicants' corresponding foreign applications.
47 Examination Report dated Oct. 6, 2008 issued by the New Zealand Patent Office in one of Applicants' corresponding foreign applications.
48 Examination Report dated Oct. 7, 2010 issued by the New Zealand Patent Office in one of Applicants' corresponding foreign applications.
49 Gainer, J.L., et al, Atherosclerosis, 19: 135-138, 1974, "Oxygen diffusion and atherosclerosis."
50 Gainer, J.L., et al, Chem. Eng. Commun., 15, pp. 323-329, 1982 "Using Excess Volume of Mixing to Correlate Diffusivities in Liquids."
51 Gainer, J.L., et al, Circulatory Shock, 41, pp. 1-7, (1993), "The Effect of Crocetin on Hemorrhagic Shock in Rats."
52 Gainer, J.L., et al, Pulmonary Pharmacology & Therapeutics, 18, pp. 213-216, 2005, "The effect of trans sodium crocetinate (TSC) in a rat oleic acid model of acute lung injury."
53 Gainer, J.L., Ind. Engr. Chem. Research, vol. 33, pp. 2341-2344, 1994 "Altering Diffusivities in Dilute Polymeric and Biological Solutions."
54 Giassi, L.J., et al, Journal of Trauma, 51, pp. 932-938, (2001), "Trans-Sodium Crocetinate Restores Blood Pressure, Heart Rate, and Plasma Lactate after Hemorrhagic Shock."
55 Giassi, L.J., et al, Journal of Trauma, 51:932-938, 2001, "Trans Sodium Crocetinate Restores Blood Pressure, Heart Rate, and Plasma Lactate after Hemorrhagic Shock."
56 Giassi, L.J., et al, Shock, 18(6), pp. 585-588 (2002), "Trans Sodium Crocetinate for Hemorrhagic Shock: Effect of Time Delay in Initiating Therapy."
57 Gibson, T.W., et al, J. Org. Chem., vol. 41, No. 5, 1976, pp. 791-793 (XP002325593).
58 Gibson, T.W., et al, J. Org. Chem., vol. 41, No. 5, 1976, pp. 791-793, (XP002325593).
59 Gill, A.L., et al, Q J Med, 97, pp. 385-395, (2004), "Hyperbaric oxygen: its uses, mechanisms of action and outcomes."
60 Goldstick, T.K., PhD Dissertation, University of California, Berkeley, CA, pp. 13-28, 1996, "Diffusion of Oxygen in Protein Solutions."
61 Gree, R., et al, Tetrahedron Letters, vol. 27, No. 41, pp. 4983-4986 (1986).
62 Greenwood, T.W., et al, Brit. J. Surg., vol. 60, No. 5, May 1973, pp. 394-397, "Hyperbaric Oxygen and Wound Healing in Post-Irradiation Head and Neck Surgery."
63 Holland, R.A.B., et al, Respiration Physiology, 59, pp. 71-91, 1985, "Kinetics of O2 Uptake and Release by Red Cells in Stopped-Flow Apparatus: Effects of unstirred Layer."
64 Holloway, G.M., et al, The American Physiological Society, 1988, pp. 683-686-Department of Chemical Engineering, and Dept. of Anesthesiology, School of Medicine, Univ. of VA, Charlotteville, Va; "The carotenoid crocetin enhances pulmonary oxygenation."
65 Holloway, G.M., et al, The American Physiological Society, 1988, pp. 683-686—Department of Chemical Engineering, and Dept. of Anesthesiology, School of Medicine, Univ. of VA, Charlotteville, Va; "The carotenoid crocetin enhances pulmonary oxygenation."
66 Hungarian Novelty Search Report dated Nov. 5, 2009 (w/translation).
67 Huxley, V.H., et al, J. Physiol., 316, pp. 75-83, (1981), "The Effect of the Red Cell Membrane and a Diffusion Boundary Layer on the Rate of Oxygen Uptake by Human Erythrocytes."
68 Huxley, V.H., et al, J. Physiol., 316, pp. 75-83, 1981, "The Effect of the Red Cell Membrane and a Diffusion Boundary Layer on the Rate of Oxygen Uptake by Human Erythrocytes."
69 India Office Action dated Oct. 23, 2008 in a corresponding application owned by the applicants (India Patent App No. 676/DELNP/2006).
70 International Preliminary Examination Report dated May 25, 2007.
71 International Preliminary Report on Patentability (Chapter 1 of the Patent Cooperation Treaty) with written opinion mailed Oct. 19, 2006 in PCT/US06/06422.
72 International Preliminary Report on Patentability, dated May 4, 2010.
73 International Preliminary Report on Patentability-issued Oct. 13, 2009 in PCT/US2008/004708.
74 International Preliminary Report on Patentability—issued Oct. 13, 2009 in PCT/US2008/004708.
75 International Search Report and Written Opinion mailed Jul. 22, 2008.
76 International Search Report and Written Opinion mailed Oct. 19, 2006 in PCT/US06/06422.
77 International Search Report dated Mar. 25, 2009 in PCT/US 08/12440.
78 International Search Report dated Sep. 1, 2010 in PCT/US 10/01794.
79 International Search Report mailed Dec. 24, 2003 in PCT/US03/05521.
80 International Search Report mailed Oct. 19, 2006 in PCT/US06/06422.
81 International Searching Authority Invitation dated Jan. 13, 2009 in PCT/US 08/12440.
82 IPRP issued in corresponding PCT Appln. No. PCT/US2008/004708.
83 Isler, O., et al, Helv. Chim. Acta, vol. 40, No. 5, 1957, pp. 1242-1249 (XP008042920).
84 Isler, O., et al, Helv. Chim. Acta, vol. 40, No. 5, 1957, pp. 1242-1249, (XP008042920).
85 Isler, O., et al, Helv. Chim. Acta, vol. 40, No. 5, 1957, pp. 1242-1249, XP008042920.
86 Isler, O., et al, Helv. Chim. Acta., vol. 40, No. 5, 1957, pp. 1242-1249.
87 Jansen, F.J.H.M., et al, Recl. Trav. Chem. Pays-Bas, 113, 552 (1994).
88 Japanese Office Action and its English Translation dated Apr. 6, 2010 in the Assignee's Japanese application relating to PCT/US2006/006422.
89 Japanese Office Action and its English Translation dated Jan. 12, 2010 in the Assignee's Japanese application relating to PCT/US 03/26424.
90 Japanese Patent Office Action dated Jun. 2, 2009 and its English translation.
91 Japanese Patent Office Action dated Jun. 9, 2009 and its English translation.
92 Johnson, M.E., et al, Journal of Pharmaceutical Sciences, vol. 85, No. 7, pp. 670-679, Jul. 1996, "Synergistic effects of chemical enhancers and therapeutic ultrasound on transdermal drug delivery."
93 Johnson, Mark E, et al, Journal of Pharmaceutical Sciences, vol. 85, No. 7, Jul. 1996, pp. 670-679, entitled "Synergistic Effects of Chemical Enhancers and Therapeutic Ultrasound on Transdermal Drug Delivery."
94 Kalani, M., et al, Journal of Diabetes & Its Complications, vol. 16, No. 2, pp. 153-158 (2002).
95 Kamiro, T., et al, Neurosurgery, vol. 49, No. 2, pp. 409-415, Aug. 2001, "Radiosurgery-induced Microvascular Alterations Precede Necrosis of the Brain Neuropil."
96 Kamiryo, T., et al, Acta Neurochir (Wien), 138, pp. 451-459, (1996), "Histological Changes in the Normal Rat Brain After Gamma Irradiation."
97 Korean Office Action and its English Translation dated Jul. 6, 2010 in the Assignee's Korean application 10-2004-7013118, that is the nationalized appln. from PCT/US03/05521, claiming priority from U.S. Appl. No. 60/358,718.
98 Korean Office Action and its English Translation dated Jun. 22, 2010 from applicant's Korean Patent Appln. No. 10-2006-7003827, that corresponds to PCT/US03/26424.
99 Korean Office Action dated May 26, 2009, and English translation in a corresponding application owned by the applicants.
100 Korean Office Action dated Nov. 23, 2009 in applicant's corresponding Korean application No. 10-2006-7003827.
101 Ladig et al, J. Am. Chem. Soc., 120, 9394-9395 (1998).
102 Ladig, K.E. et al, Altering Diffusivity in Biological Solutions through Modification of Solution Structure and Dynamics, Journal of the American Chemical Society, 1998 vol. 120, No. 36, pp. 9394-9395.
103 Ladig, K.E., et al, JACS, vol. 120, No. 36, 1998, pp. 9394-9395 (XP 002970835).
104 Ladig, K.E., et al, Journal of the American Chemical Society, vol. 120, No. 36, pp. 9394-9396, (1998), "Altering Diffusivity in Biological Solutions through Modification of Solution Structure and Dynamics."
105 Laidig, K. E., et al, Journal of the American Chemical Society, vol. 120, No. 36, pp. 9394-9395, 1998, "Altering Diffusivity in Biological Solutions through Modification of Solution Structure and Dynamics."
106 Laidig, K.E. et al, Altering Diffusivity in Biological Solutions through Modification of Solution Structure and Dynamics, Journal of the American Chemical Society, 1998, vol. 120, No. 36, pp. 9394-9395.
107 Letham, D.S., et al Phytochemistry 10, 2077 (1971).
108 Lyubimova, N., et al, The British Journal of Radiology, 77, pp. 488-492, (2004), "Experimental evidence to support the hypothesis that damage to vascular endothelium plays the primary role in the development of late radiation-induced CNS injury."
109 Marx, R.E., DDS, J. Oral Maxillofac Surg, 41, pp. 283-288, (1983), "Osteoradionecrosis: A New Concept of its Pathophysiology."
110 Marx, R.E., et al, The American Journal of Surgery, vol. 160, pp. 519-524, Nov. 1990, "Relationship of Oxygen Dose to Angiogenesis Induction in Irradiated Tissue."
111 Mayer, R., et al, Strahlenther Onkol, No. 2, pp. 113-123 (2005), "Hyperbaric Oxygen and Radiotherapy."
112 Mexican Office Action dated Feb. 23, 2009 in a corresponding application owned by the applicants (Mexican Patent App No. PA/a/2004/008253).
113 Mexican Office Action dated May 2010, and English translation of rejected parts of the Office Action, from Mexican Patent Application No. PA/a/2004/008253 corresponding to International Patent Application No. PCT/EP2003/005521.
114 Miyagawa, H., et al, Neuropathology, 16, pp. 126-132, (1996), "Pathogenesis of delayed radiation injury in the rat spinal cord after X-ray irradiation."
115 Moelbert, S., et al, Biophuysical Chemistry 112, 45-57, 2004 "Kosmotropes and chaotropes: modeling preferential exclusion, binding and aggregate stability."
116 Norwegian Office Action and its English Translation mailed Jun. 22, 2010 in the Assignee's Norwegian application relating to PCT/US03/05521.
117 Notification Concerning Transmittal of International Preliminary Report on Patentability (Chapter 1 of the Patent Cooperation Treaty), dated May 14, 2010.
118 Office Action dated Aug. 24, 2007 from U.S. Appl. No. 11/790,779.
119 Office Action dated Jun. 25, 2008 from corresponding Australian Patent Office.
120 Office Action dated Nov. 13, 2008 from U.S. Appl. No. 10/647,132.
121 Office Action dated Sep. 28, 2007 from U.S. Appl. No. 11/723,383.
122 Okeda, R., Neuropathology, 23, pp. 153-160, (2003), "Pathological changes in the cerebral medullary arteries of five autopsy cases of malignant nephrosclerosis: Observation by morphometry and reconstruction of serial sections."
123 Okonkwo, D.O., et al, Neuroscience Letters 352 (2003) 97-100, "Trans-sodium crocetinate increases oxygen delivery to brain parenchyma in rats on oxygen supplementation."
124 Okonkwo, D.O., et al, Neuroscience Letters, 352, pp. 97-100, (2003), "Trans-sodium crocetinate increases oxygen delivery to brain parenchyma in rats on oxygen supplementation."
125 Okonkwo, D.O., et al, Neuroscience Letters, 352, pp. 97-100, 2003, "Trans-sodium crocetinate increases oxygen delivery to brain Parenchyma in rats on oxygen supplementation."
126 Pauling, L., Fortschr. Chem. Org. Naturst., 3:303 (1939), p. 203-235.
127 PCT Notification dated Mar. 25, 2009 in PCT/US 08/12440.
128 Pfander, H. et al, Pure & Appl. Chem., vol. 69, No. 10, pp. 2047-2060 (1997), "Carotenoid synthesis: A progress report."
129 Polish Office Action dated Feb. 23, 2010 from Polish Patent Application No. P-373780 based on PCT/US03/05521.
130 Polish Office Action dated Sep. 2010 in corresponding Polish Application No. P-373780.
131 Pure & Appl. Chem., vol. 69, No. 10, pp. 2047-2060, 1997, "Carotenoid synthesis: A progress report."
132 RN: 120523-11-7; CN: 2,4,6,8,10,12,14,16,18-Eicosanonaenedioic acid, 4,8,13,17-tetramethyl-potassium sodium salt.
133 RN: 147484-59-1; CN: 2,4,6,8-Decatetraenedioic acid, disodium salt.
134 RN: 33261-80-2; CN: 2,4,6,8,10,12,14,16,18-Eicosanonaenedioic acid, 4,8,13,17-tetramethyl-dipotassium salt.
135 RN: 33261-81-3; CN: 2,4,6,8,10,12,14,16,18-Eicosanonaenedioic acid, 4,8,13,17-tetramethyl-disodium salt.
136 Roy, et al, Shock, vol. 10, No. 3, pp. 213-217 (1998).
137 Roy, J.W., et al, Shock, vol. 10, No. 3, pp. 213-2171, (1998), "A Novel Fluid Resuscitation Therapy for Hemorrhagic Shock."
138 Schwieter, U., et al, "Synthesen in der Carotinoid-Reiche 20. Mitteilung Neu Synthesen von Apocarotinoiden," Helvetica Chimica Acta, vol. 1, (1966), pp. 369-390, XP-002575142.
139 Secor, R.M., A.I.Ch.E. Journal, vol. 11, No. 3, pp. 452-456, 1965, "The Effect of Concentration on Diffusion Coefficient in Polymer Solutions."
140 Seyde, Walter C., et al, Journal of Cerebral Blood Flow and Metabolism, vol. 6, No. 6, 1986, pp. 703-707, "Carotenoid Compound Crocetin Improves Cerebral Oxygenation in Hemorrhaged Rats."
141 Singer et al, Crit Care Med, vol. 28, No. 6, pp. 1968-1972 (2000) Intravenous crocetinate prolongs survival in a rat model of lethal hypoxemia.
142 Singer, M., et al, Crit Care Med, vol. 28, No. 6, pp. 1968-1972, (2000), "Intravenous crocetinate prolongs survival in a rat model of lethal hypoxemia."
143 Snyder, J.M., et al, J. Am. Oil Chem. Soc., 59, 469 (1982).
144 Stennett, A.K., et al, J. Phys. Chem. B., vol. 110, No. 37, pp. 18078-18080, 2006, "trans-Sodium Crocetinate and Diffusion Enhancement."
145 Supplementary European Search Report dated Apr. 29, 2010 issued by the EPO in one of Applicants' corresponding foreign applications.
146 Supplementary Partial European Search Report dated Nov. 7, 2006.
147 Supplementary Partial European Search Report, 2005.
148 T.W. Gibson et al, J. Org. Chem., vol. 41, No. 5, 791-793 (1976); XP-002325593.
149 U.S. Appl. No. 10/647,132, filed Aug. 2003, Gainer.
150 U.S. Appl. No. 11/361,054, filed Feb. 2006, Gainer.
151 U.S. Appl. No. 60/907,718, filed Apr. 2007, Gainer.
152 U.S. Appl. No. 61/001,095, filed Oct. 2007, Gainer.
153 Ukraine Office Action issued Aug. 2010.
154 Wenkert et al, J. Org Chem. vol. 55, No. 25, 1990, pp. 6203-6214.
155 Wenkert, E. et al, Journal of Organic Chemistry, Dec. 7, 1990, Vo. 55, No. 25, pp. 6203-6214.
156 Wenkert, E., et al, J. Org. Chem., vol. 55(25), pp. 6203-6214, 1990, (XP002317164).
157 Wenkert, E., et al, J. Org. Chem., vol. 55, No. 25, 1990, pp. 6203-6214 (XP002317164).
158 Wenkert, E., et al, J. Org. Chem., vol. 55, No. 25, 1990, pp. 6203-6214, (XP002317164).
159 Wenkert, E., et al, J. Org. Chem., vol. 55, No. 25, 1990, pp. 6203-6214, XP002317164.
160 Wenkert, E., et al, J. Org. Chem., vol. 55, No. 25, 1990, pp. 6203-6214.
161 White, D.C., MD, Cancer, 37, pp. 1126-1143, February Supplement (1976), "The Histopathologic basis for functional decrements in late radiation injury in diverse organs."
162 Widmer, Erich et al, Helvetica Chemica Acta—vol. 73 (1990), pp. 861-867, Technical Procedures for the Syntheses of Carotenoids and Related Compounds . . . .
163 Wilkins, E.S., et al, Cancer Biochem. Biophys., 1979, vol. 3, pp. 71-74, "The Effect of Crocetin on the Irradiation of Walker-256: In Vitro and In Vivo Studies."
164 Williamson, et al, Int. J. Oral Maxillofac. Surg., 36, pp. 533-540, (2007), "An experimental study of the use of hyperbaric oxygen to reduce the side effects of radiation treatment for malignant disease."
165 Wirz R, Helv. Chim Acta, vol. 40, No. 5, 1957, pp. 1242-1249.
166 Wirz, R. et al, Helvetica Chimica Acta, 1960, 43(6), 1738-1745.
167 Wirz, R., et al, Helv. Chim. Acta, vol. 43(6), pp. 1738-1745, 1960, (XP008042762).
168 Wirz, R., et al, Helv. Chim. Acta, vol. 43, No. 6, 1960, pp. 1738-1745, (XP008042762).
169 Wirz, R., et al, Helv. Chim. Acta, vol. 43, No. 6, 1960, pp. 1738-1745, XP008042762.
170 Wirz, R., et al, Helv. Chim. Acta, vol. 43, No. 6, 1960, pp. 1738-1745.
171 Wirz, R., et al, Helv.Chim.Acta, vol. 43, No. 6, 1960, pp. 1738-1745 (XP008042762).
172 Written Opinion and International Search Report issued in PCT/US06/06422 dated Oct. 19, 2006.
173 Written Opinion dated Mar. 25, 2009 in PCT/US 08/12440.
174 Written Opinion dated Mar. 25, 2009 in PCT/US2008/012440 [previously submitted].
175 Written Opinion dated Sep. 1, 2010 in PCT/US 10/01794.
176 Written Opinion mailed Oct. 19, 2006 in PCT/US06/06422.
177 Wurtman, R.J., Scientific American, vol. 252, 1985 Alzheimer's Disease.
178 Yamaguchi, K., et al, J. Applied Physiology, 58: 1215-1224, 1985.
179 Yamaguchi, K., et al, the American Physiological Society, pp. 1215-1224, (1985), "Kinetics of O2 uptake and release by human erythrocytes studied by a stopped-flow technique."
180 Zheng, S., et al, "Crocetin Attenuates Atherosclerosis in Hyperlipidemic Rabbits Through Inhibition of LDL Oxidation," Journal of Cardiovascular Pharmacology, vol. 47, No. 1, Jan. 2006, pp. 70-76, XP009135396, ISSN: 0160-2446.
US8974822 * Jun 2, 2011 Mar 10, 2015 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
US9604899 Aug 8, 2011 Mar 28, 2017 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US20110300213 * Jun 2, 2011 Dec 8, 2011 Gainer John L Oral formulations of bipolar trans carotenoids
US20160199490 * Jan 11, 2016 Jul 14, 2016 Diffusion Pharmaceuticals, LLC Trans carotenoids, their synthesis, formulation and uses
U.S. Classification 514/547, 554/121
International Classification A01N37/00
Cooperative Classification C07C69/602, C07C57/13, C07C57/03, A61K41/0038, A61K31/11, A61K9/19, A61K31/202, A61N5/10, A61K45/06
European Classification C07C57/03, C07C69/602, C07C57/13
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GAINER, JOHN L.;LANZ, MARC;REEL/FRAME:017809/0435;SIGNING DATES FROM 20060308 TO 20060320
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GAINER, JOHN L.;LANZ, MARC;SIGNING DATES FROM 20060308 TO 20060320;REEL/FRAME:017809/0435